Aytu BioPharma, Inc (AYTU) stock
AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026Score 9/3079% below fair value
$1.78−0.01 (-0.56%)
Close on Nov 13, 2026Market cap $19.34MP/E –Yield –
Aytu BioPharma profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Aytu BioPharma's profit margin for the twelve months ending Jun 30, 2026 was -24.8%. For fiscal 2026 it was -24.8%, against -20.4% the year before. The highest annual figure on record is -15.9% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -24.8% | −4.3 |
| FY2025 | Jun 30, 2025 | -20.4% | +3.9 |
| FY2024 | Jun 30, 2024 | -24.3% | −8.4 |
| FY2023 | Jun 30, 2023 | -15.9% | +96.7 |
| FY2022 | Jun 30, 2022 | -112.5% | −23.7 |
| FY2021 | Jun 30, 2021 | -88.8% | −39.5 |
| FY2020 | Jun 30, 2020 | -49.3% | +321.3 |
| FY2019 | Jun 30, 2019 | -370.6% | −92.3 |
| FY2018 | Jun 30, 2018 | -278.3% | +420.3 |
| FY2017 | Jun 30, 2017 | -698.7% | +401.1 |
| FY2016 | Jun 30, 2016 | -1099.7% | +1850.6 |
| FY2015 | Jun 30, 2015 | -2950.3% | +325.0 |
| FY2013 | Aug 31, 2013 | -3275.3% | +134.7 |
| FY2012 | Aug 31, 2012 | -3410.0% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | -0.1% | +130.8 |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | -45.3% | −66.9 |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | -69.8% | −74.7 |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | 14.1% | +5.3 |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | -130.9% | −99.3 |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | 21.6% | +42.2 |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | 4.9% | +6.0 |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | 8.9% | +54.5 |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | -31.6% | −23.6 |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | -20.6% | +11.1 |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | -1.2% | +24.3 |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | -45.6% | −43.0 |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | -8.0% | +50.6 |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | -31.7% | +188.5 |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | -25.5% | +24.5 |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | -2.5% | +124.7 |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | -58.6% | +22.3 |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | -220.2% | −31.4 |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | -49.9% | +12.9 |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | -127.2% | −95.3 |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | -80.9% | −59.7 |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | -188.8% | −123.5 |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | -62.9% | −56.1 |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | -31.8% | +310.5 |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -21.2% | +825.8 |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -65.4% | +123.7 |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -6.7% | +252.7 |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -342.3% | −101.6 |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -847.0% | −906.1 |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | -189.1% | +274.8 |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | -259.5% | +89.9 |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | -240.7% | +153.7 |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | 59.1% | +866.7 |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | -463.8% | +119.9 |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | -349.4% | +257.2 |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | -394.4% | +425.8 |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | -807.6% | – |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | -583.8% | – |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | -606.6% | – |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | -820.1% | – |
See a number that looks wrong?